Compare AbbVie Inc (ABBV) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs NICE Ltd — how do they compare? AbbVie Inc trades at $249.02 (market cap $438.19B), while NICE Ltd trades at $101.62 (market cap $5.99B). The key difference: AbbVie Inc is far larger — about 73.2× NICE Ltd's market cap, and AbbVie Inc pays a 2.79% dividend while NICE Ltd pays none. Which is the better fit depends on your goals.
| ABBV | NICE | |
|---|---|---|
Market Cap | $438.19B | $5.99B |
Sector | Health | Technology |
52-Week High | $263.58 | $153.44 |
52-Week Low | $197.38 | $83.15 |
Enterprise Value | $502.45B | $5.72B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.91, up 1.57% on the day, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $3.87. Revenue growth is robust, projected at $64.4B for 2026, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive clinical trial results for ELAHERE® and institutional buying activity underscore momentum.
The outlook remains positive given earnings beats, a 70.73% buy rating from analysts, and a $281.33 consensus price target. Key risks include patent expirations in the 2030s, high debt levels, and margin pressure. The dividend yield adds income appeal, but execution on pipeline products is critical for sustained growth.
NICE stock trades at $101.85, up 4.88% today, showing strong momentum after exceeding Q2 2026 earnings expectations with $2.70 EPS versus $2.63 expected. The company maintains solid fundamentals with 65.12% gross margins and 13.86% net income margin, while technical indicators show bullish momentum with key resistance at $103. Recent partnerships with RingCentral and ESG initiatives highlight strategic growth positioning.
The outlook remains positive with analyst consensus target of $115 suggesting 13% upside potential. Key risks include competitive pressures in customer engagement software and potential margin compression as revenue growth outpaces profit growth. Institutional ownership trends show mixed activity with some firms increasing positions while others trim holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
